Latest Ratios: P/E Ratio -1.2x · EV/EBITDA N/A · ROE -125.6%. (2015–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $37M | $56M | $88M | $21M | $31M | $30M | — | — | — | — | — |
| Enterprise Value | $33M | $51M | $84M | $21M | $29M | $25M | — | — | — | — | — |
| P/E Ratio → | -1.17 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 18.08 | 27.38 | 41.09 | 9.96 | 14.85 | 20.92 | — | — | — | — | — |
| P/B Ratio | 5.28 | 8.35 | 13.68 | 3.22 | 3.60 | 2.51 | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 25.25 | 39.16 | 9.83 | 13.98 | 17.57 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 25.7% | 25.7% | 32.7% | 41.3% | 36.1% | 35.5% | 38.3% | -48.1% | -17.5% | — | — |
| Operating Margin | -408.4% | -408.4% | -312.6% | -233.6% | -199.5% | -276.3% | -275.1% | -531.4% | -1358.1% | — | — |
| Net Profit Margin | -404.1% | -404.1% | -489.9% | -263.0% | -231.3% | -592.2% | -340.5% | -754.1% | -1358.1% | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -125.6% | -125.6% | -162.9% | -73.1% | -47.1% | -88.8% | -88.2% | -216.7% | -263.7% | -3695.2% | -2599.2% |
| ROA | -109.6% | -109.6% | -139.9% | -64.6% | -43.3% | -74.3% | -53.0% | -111.7% | -224.1% | -2637.3% | -794.9% |
| ROIC | -268.1% | -268.1% | -118.2% | -56.4% | -44.8% | -37.2% | -42.2% | -120.2% | -235.4% | -162.2% | -4136.6% |
| ROCE | -125.5% | -125.5% | -102.9% | -64.0% | -40.1% | -40.7% | -68.9% | -152.7% | -263.7% | -237.8% | -2454.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.04 | 0.04 | 0.03 | 0.04 | 0.02 | 0.01 | 0.25 | 1.83 | 0.02 | 0.26 | 0.45 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.65 | -0.64 | -0.04 | -0.21 | -0.40 | 0.23 | 1.78 | -0.18 | 0.26 | -0.72 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -369.11 | -369.11 | -488.67 | -71.35 | -539.89 | -51.15 | -9.45 | -36.07 | — | — | — |
Net cash position: cash ($5M) exceeds total debt ($245490)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.36 | 6.36 | 4.88 | 1.02 | 3.60 | 7.01 | 0.12 | 0.02 | 1.47 | 3.80 | 2.58 |
| Quick Ratio | 6.21 | 6.21 | 4.66 | 0.85 | 3.29 | 6.84 | 0.10 | 0.02 | 1.47 | 3.71 | 2.03 |
| Cash Ratio | 5.83 | 5.83 | 4.39 | 0.49 | 2.65 | 6.28 | 0.06 | 0.01 | 1.18 | — | 1.86 |
| Asset Turnover | — | 0.27 | 0.29 | 0.28 | 0.22 | 0.11 | 0.10 | 0.17 | 0.09 | — | — |
| Inventory Turnover | 12.83 | 12.83 | 6.79 | 7.25 | 5.80 | 6.97 | 11.02 | 999999.00 | — | — | — |
| Days Sales Outstanding | — | 21.22 | 12.60 | 26.02 | 19.84 | 18.32 | 42.29 | 12.64 | 19.48 | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | 0.7% | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.2% | 0.0% | 0.4% | 0.4% | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.2% | 0.0% | 0.4% | 1.0% | — | — | — | — | — |
| Shares Outstanding | — | $12M | $11M | $8M | $8M | $8M | $7M | $6M | $6M | $6M | $6M |
Clinical and liquidity binary
According to current market data, NTRB trades at a P/S multiple of 18.26, which appears to reflect speculative option value on the AVERSA technology rather than the underlying revenue generation, as the company lacks meaningful earnings or cash flow to support traditional valuation metrics.
The elevated P/S ratio suggests that investors are pricing the firm as a binary clinical-stage asset rather than a commercial entity. This valuation warrants caution, as it implies significant future success for the AVERSA fentanyl patch that is not yet supported by current financial performance or regulatory milestones.
As reported in financial statements, NTRB's ROIC has consistently remained in negative territory, reaching -41.5% in 2026Q1, which indicates that the company is currently destroying shareholder value as it attempts to fund the development of its proprietary transdermal delivery systems.
The persistent negative returns on invested capital highlight the high cost of clinical development relative to the company's limited revenue base. Investors should monitor whether the company can achieve a positive inflection point in capital efficiency once the AVERSA platform moves toward potential commercialization.
Based on the quarterly data, NTRB's cash conversion cycle has shown extreme volatility, with a -183 day cycle in 2026Q1, suggesting that the company's working capital management is heavily influenced by irregular inventory and payment patterns rather than a stable, repeatable commercial process.
The wide fluctuations in days sales outstanding and days payable outstanding suggest that the company lacks a mature operational rhythm. This inconsistency may indicate that current revenue streams are not yet integrated into a scalable business model, complicating the assessment of future operational efficiency.
As indicated by recent filings, the company's current ratio of 5.26 in 2026Q1 appears superficially healthy, yet this metric masks the reality of a high cash burn rate that necessitates frequent capital market access to maintain operations through the clinical development phase.
While the current ratio suggests an ability to cover short-term obligations, the lack of recurring revenue means that liquidity is entirely dependent on the company's ability to raise external capital. This reliance on equity markets creates a structural risk of dilution that investors must weigh against the potential upside of the AVERSA pipeline.
Based on an analysis of the company's business model, the Price-to-Sales ratio is the most commonly misapplied metric, as it fails to distinguish between low-margin legacy revenue and the potential high-margin royalty streams expected from the AVERSA technology upon successful regulatory approval.
Using P/S to value NTRB ignores the structural shift the company is attempting to make from contract-like revenue to proprietary pharmaceutical licensing. Analysts should instead focus on the probability-weighted net present value of the AVERSA pipeline, as current sales figures are not representative of the company's long-term earning potential.
Includes 30+ ratios · 11 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NTRB stock.
Nutriband Inc.'s current P/E ratio is -1.2x. This places it at the 50th percentile of its historical range.
Nutriband Inc.'s return on equity (ROE) is -125.6%. The historical average is -133.3%.
Based on historical data, Nutriband Inc. is trading at a P/E of -1.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Nutriband Inc. has 25.7% gross margin and -408.4% operating margin.